drugset / Trial / NCT02124421
HOT: HIPEC in Ovarian Cancer as Initial Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Timeline
- Start
- 2014-04
- Primary completion
- 2027-08
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intrathecal |
| Comparator | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |